Plus   Neg

TAL Education Expects Q4 Revenue To Grow Y-O-Y, Sequentially

TAL Education Group (TAL), while reporting third-quarter results Thursday, said it now expects total net revenues for the fourth quarter to be between $1.175 billion and $1.201 billion, representing an increase of 37 percent to 40 percent on a year-over-year basis.

In the third quarter, TAL reported net revenues of $1.119 billion, a 35 percent increase from last year, mainly driven by an increase in total student enrollments of normal priced long-term course.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
Follow RTT